Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin

Dominik Samotij; Ewelina Gawron; Justyna Szczęch; Elżbieta Ostańska; Adam Reich

doi:10.2147/BTT.S302164

Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin

Biologics. 2021 Apr 27:15:107-113. doi: 10.2147/BTT.S302164. eCollection 2021.

Authors

Dominik Samotij¹, Ewelina Gawron¹, Justyna Szczęch¹, Elżbieta Ostańska², Adam Reich¹

Affiliations

¹ Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.
² Department of Pathology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.

Abstract

The global pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging. Various cutaneous manifestations have been observed in patients with SARS-CoV-2 infection, yet exacerbations of psoriasis have been reported sporadically. Acrodermatitis continua of Hallopeau (ACH) is an uncommon, sterile pustular dermatosis involving one or more digits. In some rare cases, ACH may evolve into generalized pustular psoriasis (GPP), which is a severe, and potentially life-threatening, form of psoriasis that manifests itself with widespread eruptions of pustules. We describe the first case of a patient in whom ACH abruptly progressed into GPP during COVID-19. A combination of infliximab and acitretin was used allowing swift clinical improvement.

Keywords: SARS-CoV-2; biologic therapy; biologics; coronavirus; psoriasis; pustular psoriasis.

Publication types

Case Reports